Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients
NCT ID: NCT07144696
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2025-08-05
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China
NCT05163054
Pilot Study of Brief Intervention to Support Diabetes Health-Related Quality of Life
NCT05234944
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
NCT04016987
Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention
NCT02510664
Effect of Structured Nutrition Education in Type 1 Diabetes
NCT01791907
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
structured education and regular follow-up
education and regular follow-up
structured education and regular follow-up
Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\'s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
structured education and regular follow-up
Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\'s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* It meets the WHO diagnostic criteria for diabetes and is diagnosed as type 1 diabetes;
* Capable and willing to participate in a 12 hour structured education course training;
* Capable and willing to accept regular outpatient follow-up visits;
* Voluntarily participate in this study and sign informed consent.
Exclusion Criteria
* Severe microvascular complications: proliferative retinopathy; Urinary albumin/creatinine\>300mg/g, or 24-hour urinary protein quantification\>1g/d; Uncontrolled painful diabetes neuropathy and significant diabetes autonomic neuropathy;
* Individuals who have undergone vascular intervention or amputation due to acute cerebrovascular accidents, acute coronary syndrome, or peripheral arterial disease requiring hospitalization within the first 3 months of selection;
* Blood pressure remains above 180/110mmHg and cannot be controlled within 160/110mmHg within one week;
* Blood creatinine clearance rate is less than 30ml/min/1.73m2 (calculated according to CKDEPI formula), alanine aminotransferase is ≥ 3 times the normal upper limit, total bilirubin is ≥ 2 times the normal upper limit and lasts for more than 1 week;
* Have used drugs that may affect blood sugar for more than one week within the past 12 weeks, such as oral/intravenous glucocorticoids, growth hormone, estrogen/progesterone, high-dose diuretics, antipsychotic drugs, etc; However, low-dose diuretics for blood pressure lowering purposes (hydrochlorothiazide\<25mg/d, indapamide ≤ 1.5mg/d), as well as physiological doses of thyroid hormones used for replacement therapy, are not subject to this restriction;
* Systemic infection or severe accompanying diseases; Patients with malignant tumors or chronic diarrhea;
* Other situations that cause participants to be unable to cooperate in completing the study, such as severe cognitive impairment, mental illness, etc.
* The subject is uncooperative, unable to follow up, or the researcher determines that they may have difficulty completing the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gu Nan
associate chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-447-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.